Tesamorelin / Ipamorelin Reference (Stacked Formulation)

Protocol Overview

Field Value
Name Tesamorelin / Ipamorelin Combination
Reference Code PHOENIX
Category Growth Hormone Secretagogue Combination (GHRH + GHSR Agonist)
Example Strength 12 mg / 2 mg (compounded formulation; varies by pharmacy)
Reference Range Half blend dose for initial tolerance assessment → Full blend dose once daily (investigational use)
Frequency Once daily
Key Safety Warning Compounded combination. Not FDA-approved as a fixed-dose blend. Contraindicated in active malignancy, pituitary dysfunction, and pregnancy. May increase IGF-1 levels. Monitor for fluid retention and glucose intolerance.

Mechanism of Action (Educational)

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog that stimulates endogenous growth hormone secretion from the anterior pituitary.

Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist that promotes pulsatile GH release without significant stimulation of cortisol or prolactin.

When administered together, the combination produces synergistic stimulation of endogenous growth hormone through complementary hypothalamic–pituitary signaling pathways.

Growth hormone pulses are typically observed within 30 minutes following administration. Body composition changes may develop gradually over several months.

Indications (Investigational / Off-Label)

Body composition research
Visceral adiposity investigations
Recovery optimization frameworks
IGF-1 modulation protocols

Administration (Protocol-Based)

Parameter Details
Route Subcutaneous
Frequency Once daily
Injection Site Abdomen (rotate sites)
Timing Bedtime preferred; empty stomach recommended

Pharmacokinetics (Component-Dependent)

Tesamorelin has a half-life of approximately 26–38 minutes. Ipamorelin has an approximate half-life of ~2 hours.

GH pulse typically occurs within 30 minutes following administration.

High glucose intake may blunt GH response. Monitoring of IGF-1 is recommended in structured protocols.

Titration Schedule (Protocol Example)

Weeks 1–2 Half blend dose once daily (tolerance assessment)
Week 3+ Full blend dose once daily

Dose escalation is guided by tolerability, fluid balance, and IGF-1 response.

Reconstitution & Concentration (Compounded Formulation Example)

Parameter Value
Diluent Bacteriostatic water
Example Reconstitution 12 mg Tesamorelin + 2 mg Ipamorelin + 2 mL diluent
Resulting Concentration Tesamorelin: 6 mg/mL
Ipamorelin: 1 mg/mL
Stability Up to 28 days refrigerated (2–8°C; varies by compounding standards)

This section is provided for arithmetic and formulation reference only.

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Safety & Contraindications (Summary)

Contraindications

Active malignancy
Pituitary dysfunction
Pregnancy or breastfeeding

Drug Interactions

Food intake may blunt GH response; fasted administration recommended

Adverse Events

Injection site reactions
Flushing
Headache
Water retention

Higher-Dose Risks

Significant edema
Glucose intolerance

Monitoring (Protocol-Based)

IGF-1 levels
Fasting glucose
Body composition metrics
Assessment of fluid retention

Disclaimer

Tesamorelin/Ipamorelin combination products are compounded formulations and are not FDA-approved as fixed-dose combinations. This content is provided for educational and professional reference purposes only. It does not constitute medical advice or prescribing guidance.

Reference Sources